The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK
Wrik Ghosh
Rose Wickstead
Lindsay Claxton
Jeanette Kusel
Matthew Taylor
Kelly Fleetwood
Ruth Pulikottil-Jacob
10.6084/m9.figshare.6445553.v1
https://adisjournals.figshare.com/articles/figure/The_Cost-Effectiveness_of_Ranibizumab_Treat_and_Extend_Regimen_Versus_Aflibercept_in_the_UK/6445553
<p><b>Article full text</b></p>
<p><br></p>
<p>The full text of this article can
be found here<b>. </b><a href="https://link.springer.com/article/10.1007/s12325-016-0367-9">https://link.springer.com/article/10.1007/s12325-016-0367-9</a></p><p></p>
<p><br></p>
<p><b>Provide enhanced content for this
article</b></p>
<p><br></p>
<p>If you are an author of this
publication and would like to provide additional enhanced content for your
article then please contact <a href="http://www.medengine.com/Redeem/âmailto:adisrapidplus@springer.comâ"><b>adisrapidplus@springer.com</b></a>.</p>
<p><br></p>
<p>The journal offers a range of
additional features designed to increase visibility and readership. All
features will be thoroughly peer reviewed to ensure the content is of the
highest scientific standard and all features are marked as ‘peer reviewed’ to
ensure readers are aware that the content has been reviewed to the same level
as the articles they are being presented alongside. Moreover, all sponsorship
and disclosure information is included to provide complete transparency and
adherence to good publication practices. This ensures that however the content
is reached the reader has a full understanding of its origin. No fees are
charged for hosting additional open access content.</p>
<p><br></p>
<p>Other enhanced features include,
but are not limited to:</p>
<p><br></p>
<p>• Slide decks</p>
<p>• Videos and animations</p>
<p>• Audio abstracts</p>
<p>• Audio slides</p>
2018-06-05 12:43:26
Age-related macular degeneration
Aflibercept
Cost-effectiveness
Ophthalmology
Ranibizumab
Treat and extend